Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2073-2076

  Lenartz, D ^a   Dott, U ^a   Menzel, J ^a   Schierholz, J M ^b   Beuth, J ^b  

^a KLINIKUM CHEMNITZ   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Galactoside specific mistletoe lectin (ML 1); Malignant glioma; Overall survival; Radiatio; Relapse free survival; Surgery

Indexed keywords

GALACTOSIDE; VISCUM ALBUM LECTIN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MALE; MULTICENTER STUDY; NEUROSURGERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CRANIOTOMY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; LIFE TABLES; MALE; MICROSURGERY; MIDDLE AGED; PLANT PREPARATIONS; PLANT PROTEINS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TOXINS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 0033877281     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Salman M: Epidemiology and factors affecting survival. In: Apuzzo MLJ (ed) Malignant cerebral glioma. Am Assoc of Neurological Surgeans, Park Ridge, USA, 95-110, 1990.
2. Levin VA, Silver, P, Hannigan J, Wara WM, Gutin PH, Davis RL and Wilson CB: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarhazine, and vincristine (PVC) over BCNU for anaplastic gliomas. Int J Radiat Oncol Phys Biol 18: 321, 1990.
3. DeVita JrVT, Hellman S Rosenberg SA: Cancer: Principles and practise of oncology, 5 th edition Lippincott-Raven, Philadelphia, USA, 1997.
4. Lenartz D, Stoffel B, Menzel J Beuth J: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16: 3799-3802, 1996.
5. Isenberg J, Stoffel B, Wolters U, Beuth J, Stuetzer H, Ko HL, Pichlmaier H: Immunostimulation by propionibacteria: Effects on immune status and antineoplastic treatment. Anticancer Res 15: 2363-2368, 1996.
6. Beuth J: Clinical relevance of immunoactive mistletoe lectin-1. Anti Cancer Drugs 8: 53-55, 1997.
7. Vermorken, JB, Claessen A, Gall H, van Holten A, van Tinteren H, Meijer S, Steffelar H, Brakenhoff J, van Bochove A, Scheper R, Meijer C, Hanna M, Pinedo H: Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Dukes B2, B3 or C colon cancer. Europ J Cancer 33: 162, 1997.
8. Beuth J, Moss RW: Immunotherapy with mistletoe lectin-1. J Oncol 30: 1-5, 1998.
9. Heiny BM, Albrecht V, Beuth J: Lehensqualitatsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalem Karzinom. Onkologe 4: 35-39, 1998.
10. Heiny BM, Beuth, J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces β-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14: 1339-1342, 1994.
11. Fischer H, Bell V: Biostatistics: A methodology for the Health Sciences. Willey and Sons, New York, USA, 1993.